Literature DB >> 15264288

Molecular characterization of a cryptic 2q37 deletion in a patient with Albright hereditary osteodystrophy-like phenotype.

N Chassaing1, P De Mas, M Tauber, M C Vincent, S Julia, G Bourrouillou, P Calvas, E Bieth.   

Abstract

The Albright hereditary osteodystrophy-like (AHO-like) syndrome was recently defined as a rare dysmorphic syndrome including brachymetaphalangism and mental retardation. This phenotype occurs in Albright hereditary osteodystrophy (AHO) but unlike it, the level of the Gs alpha protein activity is not reduced. To date 59 patients with these clinical and biochemical features have been reported, and for the majority of them (57/59) a cytogenetically visible 2q37 deletion has been observed. We report a new case of typical AHO-like syndrome with normal karyotype. Using the polymorphic marker D2S125 we found a loss of heterozygosity suggestive of a de novo 2q37 deletion of maternal origin. This hypothesis was confirmed by FISH analysis with a subtelomeric 2q probe containing the D2S90 marker. Genotypic analysis allowed us to map the proximal breakpoint of the subtelomeric deletion within an interval delimited by D2S2338 (present) and D2S2253 (deleted). This 2q subtelomeric deletion as small as 4 Mb is to date the smallest one observed in association with a typical AHO-like phenotype, and allows us to move the centromeric boundary of the AHO-like critical region by 750 kb towards the 2q telomere. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15264288     DOI: 10.1002/ajmg.a.30199

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

Review 1.  Class II histone deacetylases: from sequence to function, regulation, and clinical implication.

Authors:  Xiang-Jiao Yang; Serge Grégoire
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

2.  A genome-wide scan for genes involved in primary vesicoureteric reflux.

Authors:  H Kelly; C M Molony; J M Darlow; M E Pirker; A Yoneda; A J Green; P Puri; D E Barton
Journal:  J Med Genet       Date:  2007-07-27       Impact factor: 6.318

Review 3.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

4.  The 2q37-deletion syndrome: an update of the clinical spectrum including overweight, brachydactyly and behavioural features in 14 new patients.

Authors:  Camille Leroy; Emilie Landais; Sylvain Briault; Albert David; Olivier Tassy; Nicolas Gruchy; Bruno Delobel; Marie-José Grégoire; Bruno Leheup; Laurence Taine; Didier Lacombe; Marie-Ange Delrue; Annick Toutain; Agathe Paubel; Francine Mugneret; Christel Thauvin-Robinet; Stéphanie Arpin; Cedric Le Caignec; Philippe Jonveaux; Mylène Beri; Nathalie Leporrier; Jacques Motte; Caroline Fiquet; Olivier Brichet; Monique Mozelle-Nivoix; Pascal Sabouraud; Nathalie Golovkine; Nathalie Bednarek; Dominique Gaillard; Martine Doco-Fenzy
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

Review 5.  The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.

Authors:  María Isabel Cuartero; Juan de la Parra; Alicia García-Culebras; Iván Ballesteros; Ignacio Lizasoain; María Ángeles Moro
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

6.  Association of GNAS imprinting defects and deletions of chromosome 2 in two patients: clues explaining phenotypic heterogeneity in pseudohypoparathyroidism type 1B/iPPSD3.

Authors:  F M Elli; L deSanctis; M A Maffini; P Bordogna; D Tessaris; A Pirelli; M Arosio; A Linglart; G Mantovani
Journal:  Clin Epigenetics       Date:  2019-01-07       Impact factor: 6.551

7.  Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

Authors:  Kylie M Drake; E Cristy Ruteshouser; Rachael Natrajan; Phyllis Harbor; Jenny Wegert; Manfred Gessler; Kathy Pritchard-Jones; Paul Grundy; Jeffrey Dome; Vicki Huff; Chris Jones; Micheala A Aldred
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.